The U.S. Food and Drug Administration (FDA) has launched a new unified platform designed to modernize how adverse event reports are tracked and analyzed across regulated products.
The new platform, called the FDA Adverse Event Monitoring System (AEMS), consolidates multiple legacy reporting systems into a single searchable dashboard. The system is intended to improve transparency, strengthen post-market safety surveillance, and make critical safety data easier to access for regulators, researchers, manufacturers, and the public.
For companies importing, manufacturing, or distributing FDA-regulated products such as pharmaceuticals, medical devices, food, cosmetics, biologics, and dietary supplements, this development represents a significant change in how safety data can be monitored across the marketplace.
What Is the FDA Adverse Event Monitoring System (AEMS)?
AEMS is a centralized reporting and analytics platform that allows adverse event reports submitted to the FDA to be reviewed in one integrated system.
Previously, adverse event reports were spread across multiple databases, making it difficult to quickly identify trends or search across product categories. The FDA historically processed approximately six million adverse event reports each year across seven separate systems.
With AEMS, reports related to drugs, biologics, vaccines, cosmetics, foods, medical devices, animal products, and tobacco products can now be displayed in a single streamlined dashboard. The FDA also plans to migrate historical data into the new system over the coming months.
Once fully implemented, AEMS will serve as the primary adverse event monitoring platform for all FDA-regulated products.
Legacy Systems Being Replaced
The new AEMS platform replaces several longstanding FDA reporting systems.
Systems already being consolidated include:
- FAERS (FDA Adverse Event Reporting System), which contains reports for drugs, biologics, cosmetics, and color additives
- VAERS (Vaccine Adverse Event Reporting System), which contains reports for vaccines and is co-managed by the FDA and the Centers for Disease Control and Prevention
- AERS databases used for animal drugs and animal foods
Additional systems scheduled for migration into AEMS by May 2026 include:
- MAUDE (Manufacturer and User Facility Device Experience), which contains reports related to medical devices
- HFCS (Human Foods Complaint System), which contains reports related to human foods and dietary supplements
- CTPAE (Center for Tobacco Products Adverse Event Reporting System), which contains reports related to electronic nicotine delivery systems and other tobacco products
By the end of May 2026, AEMS is expected to contain real-time adverse event reports for all FDA-regulated products.
Real-Time Reporting and Increased Transparency
One of the most significant changes introduced with AEMS is the transition to real-time publication of adverse event reports.
Historically, adverse event data was released on a quarterly basis, which limited the ability of regulators, researchers, and industry stakeholders to quickly identify potential safety signals.
With AEMS, adverse event reports will be published in near real time, while still protecting individually identifiable patient or consumer information. The FDA expects this increased transparency to reduce the number of Freedom of Information Act (FOIA) requests submitted for adverse event data.
The agency also plans to introduce enhanced data analytics tools and application program interfaces (APIs) that will make it easier to analyze safety data across product categories.
Why This Matters for Importers, Manufacturers, and the Marketplace
Adverse event reports are a key component of the FDA’s post-market surveillance system. These reports are submitted by patients, healthcare professionals, consumers, and manufacturers and help regulators identify potential safety concerns associated with regulated products.
Although adverse event reports alone do not establish causation, they can reveal patterns or clusters that may signal previously unknown risks.
The new AEMS platform also provides companies with an opportunity to monitor what is being reported in the marketplace about their products and those of their competitors. With more accessible and searchable safety data, manufacturers, importers, and distributors can better understand potential safety signals, emerging issues, or product complaints that may affect their industry.
For companies involved in importing or distributing FDA-regulated products, this platform may provide valuable insight into:
- safety trends associated with specific products or ingredients
- adverse event reports linked to competing products
- emerging regulatory or safety concerns in the marketplace
- broader industry risk signals affecting regulated product categories
This level of visibility may help companies strengthen internal compliance, monitor product performance, and stay informed about safety developments that could affect supply chains or regulatory oversight.
Efficiency and Cost Savings
Maintaining multiple legacy adverse event databases cost the FDA approximately $37 million annually.
By consolidating reporting systems into AEMS, the FDA expects to save approximately $120 million over the next five years. The new system also improves the usability of adverse event data, replacing older platforms that were difficult to search and navigate.
The modernization initiative is part of the FDA’s broader effort to improve regulatory infrastructure and strengthen its ability to monitor product safety.
Looking Ahead
The FDA plans to complete the migration of remaining reporting systems into AEMS by May 2026. At that point, the platform will provide a centralized and searchable source of real-time adverse event data across all FDA-regulated product categories.
For companies operating in regulated supply chains, the new system represents an important tool for monitoring safety trends and maintaining awareness of potential risks affecting products in the marketplace.
Need Guidance on FDA-Regulated Imports?
Alba supports importers navigating the complex regulatory landscape governing FDA-regulated goods, including food, pharmaceuticals, medical devices, cosmetics, and dietary supplements.
If you have questions about FDA compliance, import procedures, or regulatory developments affecting your supply chain, our team can help.
Contact Alba:
https://albawheelsup.com/contact-us/
